V-9302 is primarily used in research settings to study its role as a selective inhibitor of the amino acid transporter ASCT2. This transporter is implicated in the uptake of glutamine, which is crucial for the growth and survival of certain cancer cells. By inhibiting ASCT2, V-9302 helps researchers explore potential therapeutic strategies for targeting cancer metabolism, particularly in tumors that rely heavily on glutamine for their proliferation. Additionally, it is employed in preclinical studies to investigate its effects on reducing tumor growth and enhancing the efficacy of other cancer treatments. Its application extends to understanding the broader mechanisms of amino acid transport and its impact on cellular function and disease progression.